<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01851850</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-91067</org_study_id>
    <nct_id>NCT01851850</nct_id>
  </id_info>
  <brief_title>Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial</brief_title>
  <official_title>Continue Providing Care for Patient Who Participated in the BIA 9-1067-302 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to extend the use of opicapone 25 or 50mg once per day by
      subjects who participated in the BIA 9-1067-302 clinical trial according form 4a for
      additional three years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">May 24, 2016</completion_date>
  <primary_completion_date type="Actual">May 24, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>off periods</measure>
    <time_frame>6 month</time_frame>
    <description>number of &quot;off&quot; periods during the day without worsening dyskinesia.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opicapone</intervention_name>
    <description>25mg or 50mg once per day</description>
    <arm_group_label>Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis with PD

          -  subjects who are willing to participate in the trial.

          -  subjects who participated in the BIA 9-1067-302 clinical trial.

        Exclusion Criteria:

          -  subjects who didn't take part at the BIA 9-1067-302 clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tiqva</city>
        <state>Hamerkaz</state>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>May 1, 2013</study_first_submitted>
  <study_first_submitted_qc>May 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2013</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD</keyword>
  <keyword>Off periods</keyword>
  <keyword>quality of life</keyword>
  <keyword>dyskinesia</keyword>
  <keyword>end-off-dose motor fluctuations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opicapone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

